Blueshift Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Blueshift Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,007	Closed	-$409K	–	456
2023 Q2	$409K	Buy	+4,007	New	+$379K	0.16%	161
2021 Q2	–	Sell	-2,991	Closed	-$298K	–	1238
2021 Q1	$298K	Buy	+2,991	New	+$349K	0.03%	641

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Blueshift Asset Management's RETA Position: Q3 2023 in Review

Blueshift Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 4,007 shares — an estimated $409K sold.

Blueshift Asset Management first reported a position in RETA in Q1 2021 and held it in 2 quarters. The position peaked at $409K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Blueshift Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Blueshift Asset Management sold 4,007 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $409K.
Blueshift Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 2 quarters.
Blueshift Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $409K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Blueshift Asset Management's 13F filing for Q3 2023, filed 8 Nov 2023.